IPP Bureau
Novartis collaborates with BeiGene to strengthen immunotherapy pipeline
By IPP Bureau - December 21, 2021
Innovative market development collaboration also signed, expanding the availability of select Novartis oncology products in regions across China currently not covered by Novartis
U.S. FDA approves first and only injectable option for HIV prevention
By IPP Bureau - December 21, 2021
Given as few as six times per year and demonstrated superior efficacy to a daily oral PrEP option (FTC/TDF tablets) in reducing the risk of HIV acquisition
Curran Biotech’s develops nano coating to combat Covid-19 variants
By IPP Bureau - December 21, 2021
The revolutionary new nano coating is easy to apply and rejects liquid-based contagions like COVID-19/SARS-CoV-2 and variants, influenzas, and rhinoviruses and is available via ready-to-use sprays or pre-treated air filters
NMPA approves CStone's NDA for Cejemly
By IPP Bureau - December 21, 2021
The NMPA approval is based on the positive data of GEMSTONE-302 study, a multi-center, randomized, double-blind, phase III study that evaluated the efficacy and safety of Cejemly or placebo in combination with chemotherapy in first-line stage IV NSCLC patients
Salesforce and Azim Premji Foundation launch VaxIT app to speed up Covid-19 vaccination
By IPP Bureau - December 21, 2021
The VaxIT app, developed on the Salesforce platform for Azim Premji Foundation and its partners, captures the status of vaccinations to help individuals plan and stay updated on their progress
Shilpa Medicare launch Prucalshil for treatment of constipation
By IPP Bureau - December 21, 2021
Prucalopride medicine in the form of Orally Disintegrating Strips are most convenient dosage form for geriatric patients
U.S. FDA approves ANI’s rifabutin capsules, launch soon
By IPP Bureau - December 21, 2021
The capsules are the generic version of the reference listed drug Mycobutin
Cipla receives final approval for Lanreotide injection
By IPP Bureau - December 20, 2021
It is indicated for the treatment of patients with acromegaly and Gastroenteropancreatic Neuroendocrine Tumours
WHO grants EUL for Covovax
By IPP Bureau - December 20, 2021
First Emergency Use Listing granted by WHO for a protein-based Covid-19 vaccine
Gamaleya claims the Sputnik V perfect booster against Omicron
By IPP Bureau - December 20, 2021
Sputnik Light as a booster significantly increases virus-neutralizing activity against Omicron based on sera 2-3 months after revaccination and is a universal booster to other vaccines inducing stronger antibody and T-cell response
Merck’s tepmetko receives positive CHMP opinion in Europe
By IPP Bureau - December 20, 2021
The medicine is the first and only oral MET inhibitor to receive CHMP positive opinion in Europe for adult patients with advanced NSCLC harbouring alterations leading to METex14 skipping
Beghou Consulting opens office in Pune to assist life sciences firms
By IPP Bureau - December 20, 2021
The company will collaborate with U.S.-based colleagues to help life sciences companies improve commercial effectiveness
ICMR invites EOI for Omicron detection kits
By IPP Bureau - December 20, 2021
The Indian Council of Medical Research (ICMR), intends to enter into non-exclusive agreements with companies
Moderna says Covid-19 booster dose works against Omicron in lab study
By IPP Bureau - December 20, 2021
Authorized booster increases Omicron neutralizing antibody levels approximately 37-fold
TeleRay and Radiobotics to provide radiology AI
By IPP Bureau - December 20, 2021
TeleRay partners with Radiobotics, adding Artificial Intelligence to their pre-existing integrated best-in-class medical image and patient information distribution platform
